ArticleFrontiers in pediatrics2026
The association between dysglycemia and neonatal respiratory distress syndrome severity as well as short-term clinical outcomes at hospital admission.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the impact of admission blood glucose levels on disease severity and short-term outcomes in neonates with neonatal respiratory distress syndrome (NRDS). Methods: This retrospective cohort study included 219 NRDS neonates admitted to a tertiary hospital in China (August 2022-April 2024). Participants were categorized into hypoglycemia ( Results: The incidence of severe NRDS was significantly higher in the hyperglycemia group compared to the normoglycemia group (56.4% vs. 38.7%, Conclusion: Admission hyperglycemia predicts severe NRDS, prolonged respiratory support, and distinct complication profiles. Both hypoglycemia and hyperglycemia demonstrate specific independent predictors linked to metabolic disturbances and increased treatment demands. These findings highlight the clinical relevance of early glucose monitoring, providing new insights that admission dysglycemia may serve as an early biomarker of disease severity to guide risk stratification and personalized management of NRDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.